Viral hepatitis is a major public health threat and a leading cause of death worldwide.
Annual mortality from viral hepatitis is similar to that of other major infectious diseases such …

Background and Aims Activation of the antitumor immune response using programmed
death receptor‐1 (PD‐1) blockade showed benefit only in a fraction of patients with …

Viral hepatitis affects more than 320 million people globally, leading to significant morbidity
and mortality due to liver failure and hepatocellular carcinoma (HCC). More than 248 million …

Introduction The prevalence of hepatitis B virus (HBV) infection in Australia is nearly 1%. In
certain well defined groups the prevalence is far greater, yet an estimated 27% of people …

Background Experiences of stigma and discrimination can act as a significant barrier to
testing, monitoring, and treatment for hepatitis B virus (HBV). Aboriginal and Torres Strait …

Background and Aims Chronic hepatitis B (CHB) is a significant global health concern, and
the most prevalent blood‐borne virus in Australia. World Health Organization (WHO) …

Hepatitis B infection (HBV) is one of the most common causes of hepatocellular carcinoma
(HCC) worldwide. The age of occurrence, prognosis and incidence vary dramatically …

Objective Investigate the cascade of care for chronic hepatitis B (CHB) and estimate impacts
of increasing treatment uptake on attributable burden, according to jurisdiction. Methods A …

Introduction Individuals with chronic hepatitis B virus (HBV) infection or past exposure to
HBV infection have a substantial risk of reactivation during immunosuppressive cancer …

Objective To estimate the cultural and linguistic diversity in Australians currently living with
chronic hepatitis B (CHB), the majority of whom were born overseas, and to identify trends in …